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The B cell antigen receptor (BCR)–mediated activation of I
 
 
 
B kinase (IKK) and nuclear factor–
 
 
 
B require protein kinase C (PKC)
 
 
 
; however, the mechanism by which PKC
 
 
 
 regulates IKK 
is unclear. Here, we demonstrate that another protein kinase, TGF
 
 
 
-activated kinase (TAK)1, 
is essential for IKK activation in response to BCR stimulation. TAK1 interacts with the 
phosphorylated CARMA1 (also known as caspase recruitment domain [CARD]11, Bimp3) and 
this interaction is mediated by PKC
 
 
 
. IKK is also recruited to the CARMA1–Bcl10–mucosal-
associated lymphoid tissue 1 adaptor complex in a PKC
 
 
 
-dependent manner. Hence, our 
data suggest that phosphorylation of CARMA1, mediated by PKC
 
 
 
, brings two key protein 
kinases, TAK1 and IKK, into close proximity, thereby allowing TAK1 to phosphorylate IKK.
 
Triggering of the B cell antigen receptor
(BCR) leads to the initiation of multiple signal-
ing pathways that regulate cellular proliferation
and survival of immature and naive B lympho-
cytes, and the effector functions of mature B
cells (1). Among them, the signaling pathway
that leads to the activation of transcription factors
of NF-
 
 
 
B has a crucial role in these processes (2–
4). NF-
 
 
 
B is also activated in response to variety
of other stimuli such as CD40 or Toll-like
receptors, therefore raising the possibility of
the existence of signal-specific pathways for
activation (5, 6). The common feature of signals
that induce NF-
 
 
 
B is activation of an I
 
 
 
B kinase
(IKK) complex consisting of two catalytic sub-
units, IKK
 
 
 
 and IKK
 
 
 
, and an essential regu-
latory subunit NF-
 
 
 
B essential modulator
(NEMO)/IKK
 
 
 
. In the canonical pathway,
IKK
 
 
 
 activation results in phosphorylation and
subsequent degradation of I
 
 
 
Bs, thereby allow-
ing NF-
 
 
 
B proteins to translocate to the nucleus
(6–8). BCR signal largely utilizes this pathway
to activate NF-
 
 
 
B.
Upon BCR-mediated signaling, protein
kinase C (PKC)
 
 
 
 is activated, which in turn is
important for IKK activation (9–11). By other
stimuli including IL-1 and TNF-
 
 
 
, TGF
 
 
 
-
activated kinase (TAK)1, another protein kinase
and a member of the mitogen-activated protein
(MAP) 3 kinase family, has been reported to
participate in IKK activation (12–19). In addition
to PKC
 
 
 
, BCR stimulation requires adaptor
molecules, CARMA1 (also known as caspase
recruitment domain [CARD]11, Bimp3),
Bcl10, and mucosal-associated lymphoid tissue
(MALT)1, to activate NF-
 
 
 
B (3, 20). Indeed,
B cells lacking any of these proteins are defec-
tive in IKK activation in response to BCR
stimulation (21–27). CARMA1 contains a set
of motifs (PDZ, SH3, and GUK domains) that
define the membrane-associated guanylate kinase
(MAGUK) family, peripheral membrane pro-
teins that serve as molecular scaffolds by cluster-
ing  different signaling and structural proteins
into membrane subdomains (28, 29). In over-
expression studies, CARMA1 directly binds to
Bcl10 through CARD–CARD interactions
and Bcl10 interacts with MALT1 (28, 30–32).
Recently, MALT1 and Bcl10 have been
shown to mediate IKK activation by facilitating
the K63 polyubiquitination of the IKK
 
 
 
 (33–
36), although it remains obscure whether this
polyubiquitination event suffices for IKK activa-
tion in the context of antigen receptor signaling.
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Although adaptor proteins that participate in BCR-
mediated IKK activation have been intensively identified, it
remains unclear whether the PKC
 
 
 
 and CARMA1–Bcl10–
MALT1 complex connect and how, if any, these connec-
tions lead to IKK activation. Here, we report that BCR-
induced phosphorylation of CARMA1, mediated by PKC
 
 
 
,
contributes to bringing two key protein kinases, TAK1 and
IKK, into close proximity. As a result, TAK1 is able to
function as an upstream kinase for IKK activation in BCR
signaling context.
 
RESULTS
TAK1 is required for BCR-mediated IKK activation
 
Given the previous evidence that BCR-mediated IKK ac-
tivation is impaired in protein kinase C (PKC)
 
 
 
- or
CARMA1-deficient primary B cells (10, 11, 21–24), we
examined whether requirement for these molecules is reca-
pitulated in DT40 B cells. For this purpose, we established
PKC
 
 
 
- or CARMA1-deficient cells. As shown in Fig. 1,
both of these deficient DT40 cells failed to activate IKK
and degrade I
 
 
 
B
 
 
 
 upon BCR engagement. The defective
NF-
 
 
 
B activation in PKC
 
 
 
- or CARMA1-deficient DT40
cells was not due to the decreased BCR expression (Fig. S1
B, available at http://www.jem.org/cgi/content/full/
jem.20051591/DC1). These observations allowed us to
choose the chicken DT40 B cell system for elucidating the
molecular connections between PKC
 
 
 
 and IKK in BCR
signaling. Expression of BCR and signaling molecules in
various mutant DT40 B cell lines used in this study are
presented in Fig. S1.
Activation of IKK by all proinflammatory and innate im-
mune stimuli depends on phosphorylation of either IKK
 
 
 
 or
IKK
 
 
 
 catalytic subunits at two conserved serines located
within their activation loops (37). Such phosphorylation
could be achieved through the action of an upstream kinase.
If this is the case in BCR signaling, the aforementioned data
suggest that PKC
 
 
 
 or another kinase functions as the up-
stream kinase in IKK activation. In this regard, recent reports
have implicated MAP3 kinases, including TAK1, as a candi-
date kinase (14–16, 34). To address the role played by TAK1
in BCR-mediated IKK activation, we first examined
whether TAK1 is indeed activated by BCR ligation. TAK1
was reported to be activated via autophosphorylation after
exposure of cells to IL-1 (38, 39). Therefore, TAK1 was im-
munoprecipitated from resting and activated primary murine
B cells and we measured its in vitro autophosphorylation ac-
tivity. TAK1 was activated at least 3 min after BCR cross-
linking (Fig. 2 A). Although we used this assay for DT40 B
cells, enhancement of its in vitro kinase activity could not be
reproducibly observed. To circumvent this potential diffi-
culty in DT40 B cells, we took another approach. The status
of serine/threonine phosphorylation of Flag-tagged TAK1
was monitored in DT40 B cells after BCR cross-linking.
This tagged TAK1 underwent phosphorylation 3 min after
BCR cross-linking, whereas its kinase-deficient mutant
barely did (Fig. 2 D, top). Together, we conclude that
TAK1 is activated by BCR ligation in primary B cells and
probably in DT40 B cells.
Next, to directly examine the functional role of TAK1,
we established a DT40 cell line deficient in this molecule
(Fig. S1 A). As shown in Fig. 2 B, BCR-mediated NF-
 
 
 
B
activation was abolished in TAK1-deficient DT40 B cells.
Effects of TAK1 on key MAP kinases, extracellular signal–
regulated kinase (ERK) and c-Jun NH
 
2
 
-terminal kinase
(JNK), were also analyzed by Western blotting with anti-
bodies (Abs) specific for their phosphorylated forms. ERK
kinase in TAK1-deficient cells was activated normally by
BCR cross-linking, but JNK phosphorylation was com-
pletely abolished (Fig. 2 C). Activation of IKK and JNK by
BCR ligation was restored by introduction of wild-type
TAK1 into TAK1-deficient cells, but not by its kinase mu-
tant (Fig. 2 D). Thus, we conclude that TAK1 kinase activ-
ity is required for BCR-mediated IKK and JNK activation
in DT40 B cells.
 
Normal PKC
 
 
 
 activation in the absence of TAK1
 
As demonstrated before, TAK1-deficient DT40 B cells mani-
fested the similar defect in BCR-mediated IKK activation to
that in PKC
 
 
 
- and CARM1-deficient B cells, suggesting the
functional interaction between TAK1 and PKC
 
 
 
/CARMA1.
Thus, to elucidate the mechanism by which TAK1 participates
in BCR-mediated IKK activation, we first examined the effects
of deletion of TAK1 on PKC
 
 
 
 and CARMA1. As for its effect
Figure 1. PKC  and CARMA1 are essential for IKK activation in 
DT40 cells. BCR-mediated IKK activation in DT40 wild-type (wt), PKC - 
(PKC  / ), and CARMA1-deficient (CARMA1 / ) DT40 B cells. For IKK activa-
tion, 107 cells/lane were subjected to IKK kinase assay. IKK kinsae activity was 
measured by phosphorylation of GST-I B  as a substrate and detected by 
anti–phospho-I B  mAb (top). I B  degradation was analyzed by Western 
blotting with anti-I B  Ab (middle). NF- B activity was examined by EMSA 
(bottom). Position of the NF- B complex is indicated by arrow. 
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on PKC
 
 
 
, the activation status of PKC
 
 
 
 was, as judged by us-
ing anti–phospho-PKC
 
 
 
 Ab, not affected in TAK1-deficient
DT40 B cell (Fig. 3 A). Thus, PKC
 
 
 
 likely lies upstream of
TAK1, thereby contributing to BCR-mediated IKK activation.
As a readout of CARMA1 action, we considered the possibility
that CARMA1 might undergo serine/threonine phosphoryla-
tion upon BCR engagement because a physical interaction be-
tween CARMA1 with PKC
 
 
 
 was reported in nonlymphoid
cells (40). Indeed, CARMA1 underwent phosphorylation, as
determined by anti–phospho-serine/threonine Ab by BCR
cross-linking in DT40 B cells. This CARMA1 phosphorylation
occurred even in TAK1-deficient cells, but the extent was de-
creased by 
 
 
 
20% at 3 min after stimulation when compared
with wild-type cells (Fig. 3 B).
In the absence of PKC
 
 
 
 or CARMA1, TAK1 activa-
tion, judged by anti–phospho-serine/threonine blotting, was
greatly decreased, compared with wild-type DT40 B cells
(Fig. 3 C). These observations suggest that PKC
 
 
 
- and
CARMA1-mediated events augment TAK1 activity during
BCR signaling.
 
Interaction of TAK1 with CARMA1
 
To further address the mechanism by which TAK1 leads to
the activation of IKK, we analyzed whether TAK1 interacts
with PKC
 
 
 
 and/or CARMA1 in DT40 B cells that are un-
stimulated or stimulated. Efficient interaction between
TAK1 and CARMA1 was observed in stimulated B cells
(Fig. 4 A). This inducible association was also observed in
Figure 2. TAK1 is required for BCR-mediated IKK activation. (A) For 
TAK1 activation, primary B cells from spleens of C57BL/6J mice were purified 
and stimulated by anti–mouse IgM F(ab)2 (anti- ). Cytosolic extracts from 
4   107 cells per sample were immunoprecipitated with anti-TAK1 Ab, and 
the resulting immunocomplexes were subjected to in vitro kinase assay. To 
measure the activity of TAK1, autophosphorylation of TAK1 was detected 
by anti–phospho-serine/threonine (P-ST) Abs. (B) IKK activity, degradation 
of I B , and NF- B activation in TAK1-deficient DT40 cells (TAK / ) or 
DT40 wild-type cells (wt) were determined with the same procedures as in 
Fig. 1. (C) For ERK activation, whole cell lysates (106 cells/ lane) were analyzed 
by Western blotting with anti–phospho-p44/p42 MAP kinase polyclonal Ab. 
For JNK activation, 2   107 cells were used for in vitro kinase assay as 
described in Materials and methods. (D) For TAK1 activity in DT40 cells, 
Flag-tagged wild type TAK1 (TAK1 wt) or kinase-dead TAK1 (TAK1 K63W) 
was transfected into TAK1-deficient DT40 cells. Cell lysates (2   107 cells/ 
lane) were immunoprecipitated with anti-Flag mAb and analyzed by Western 
blotting using anti–phospho-serine/threonine Abs. IKK kinase assay and 
detection of I B  degradation were performed as in Fig. 1. 
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primary B cells after BCR stimulation (Fig. 4 B). Although
fivefold higher amount of TAK1 was immunoprecipitated,
we could not detect reproducible association of TAK1 with
PKC
 
 
 
 (unpublished data). To assess the functional impor-
tance of this association, we made TAK1 mutants and exam-
ined their functions. The COOH-terminal region of TAK1
(402–579 amino acids) is thought to bind to a TAK1-bind-
ing protein, TAB2, in the IL-1 signaling pathway (41). In
contrast with the dB mutant, the dA mutant failed to associ-
ate with CARMA1 upon BCR engagement and to activate
IKK (Fig. 5, A–C). This failure was not due to its defective
kinase activity because the immunoprecipitated dA TAK1
mutant, once overexpressed in 293T cells, exhibited the
similar kinase activity to that of wild-type (Fig. 5 D). There-
fore, we conclude that after BCR stimulation, TAK1 is re-
cruited to CARMA1 directly or indirectly, which in turn
contributes to subsequent IKK activation.
 
Interaction of TAK1 with CARMA1 is dependent on PKC
 
 
 
Having demonstrated the necessity of interaction between
TAK1 and CARMA1 in BCR-mediated IKK activation,
next we determined how this association is formed. As
CARMA1 was phosphorylated by BCR stimulation, we rea-
soned that BCR-induced interaction between TAK1 and
CARMA1 might be associated with CARMA1 phosphoryla-
tion status. As shown before, phosphorylation of CARMA1 at
3 min after BCR stimulation occurred in TAK-deficient
DT40 B cells. Thus, we considered PKC
 
 
 
 as a key kinase for
initiating phosphorylation of CARMA1 after BCR stimula-
tion. In the absence of PKC , the phosphorylation of
CARMA1 was not induced by BCR ligation (Fig. 6 A). Im-
portantly, BCR-mediated interaction between TAK1 and
CARMA1 was also greatly reduced in PKC -deficient DT40
B cells. Thus, at 3 min after BCR stimulation, the CARMA1
phosphorylation status appeared to be well correlated with the
interaction status between TAK1 with CARMA1 (Fig. 6, A
and B). Moreover, comparison of wild-type and PKC -defi-
cient DT40 B cells indicated that inducible association of
CARMA1 with Bcl10 and MALT1 was also well correlated
with the phosphorylation status of CARMA1 at 3 min after
receptor ligation (Fig. 6 C). Together, these observations sug-
gest that the initial phase of CARMA1 phosphorylation could
contribute to its inducible association with TAK1 and Bcl10.
Although CARMA1 phosphorylation, judged by anti–
phospho-serine/threonine Ab, continued 10 min after BCR
ligation, its association with TAK1 and Bcl10 was decreased
to an almost resting level (Fig. 6, A–C). Assuming that
CARMA1 undergoes phosphorylation on multiple serine
and threonine residues upon BCR stimulation, one of the
straightforward explanations for these observations is that the
initial phosphorylation sites could contribute to association
Figure 3. Normal PKC  activation in the absence of TAK1. (A) PKC  
activity was determined by phosphorylation status using anti–phospho-
PKC  Ab (T500; corresponding to human PKC  threonine 500) in wild-
type (wt) or TAK /  DT40 cells. (B) For phosphorylation of CARMA1 in 
wild-type or TAK /  DT40 cells, cytosolic extracts from 4   107 cells per 
sample were immunoprecipitated with anti-CARMA1 Ab and analyzed by 
Western blotting using anti–phospho-serine/ threonine Abs (P-ST). (C) For 
TAK1 activity in various mutant DT40 cells, Flag-tagged wild-type TAK1 
(TAK1 wt) was transfected into TAK / , PKC  / , or CARMA1 /  DT40 
cells. Activation status of TAK1 was determined as in Fig. 2 D.
Figure 4. TAK1 associates with CARMA1. (A) For detection of molecular 
interaction, cell lysates from TAK1-deficient DT40 cells expressing Flag-
tagged wild-type TAK1 were immunoprecipitated with anti-Flag mAb and 
analyzed by Western blotting using anti-CARMA1 Ab. (B) The primary B 
cells from spleens of C57BL/6J mice were purified and stimulated by anti–
mouse IgM F(ab)2 (anti- ). Cytosolic extracts from 4   107 cells per sample 
were immunoprecipitated with anti-CARMA1 Ab, and the immuno-
complexes were subjected to Western blotting using anti-TAK1 Ab.JEM VOL. 202, November 21, 2005 1427
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of CARMA1 with TAK1 and Bcl10, whereas the sites, be-
ing phosphorylated in the later phase (10 min after stimula-
tion), could play a negative role in its association.
TAK1 is able to phosphorylate IKK
Given the importance of the CARMA1–Bcl10–MALT1
complex in IKK activation, the aforementioned data suggest
that TAK1, when interacted with the phosphorylated
CARMA1, gains access to its substrate IKK, which in turn
transphosphorylates conserved serines located within the ac-
tivation loop of IKK /IKK . Hence, to test this hypothesis,
we examined whether IKK is associated with CARMA1 af-
ter BCR cross-linking and, if so, whether this association is
dependent on PKC . As demonstrated in Fig. 7 A, this in-
ducible association was detected and dependent on PKC .
We also tested whether TAK1 is able to phosphorylate
IKK . For this purpose, transfected Flag-tagged TAK1 and
its kinase-defective mutant were immunoprecipitated from
stimulated DT40 B cells, and incubated with recombinant
glutathione  S-transferase (GST)-IKK  as a substrate. As
demonstrated in Fig. 7 B, only wild-type TAK1 led to
strong phosphorylation of recombinant GST-IKK   after
Figure 5. Requirement for interaction between TAK1 and CARMA1 
in NF- B activation. (A) Schematic diagram of various TAK1 mutant con-
structs. (B) Interaction of various mutant TAK1 with CARMA1. TAK1 mutants 
were transfected into TAK1-deficient DT40 cells. Cell lysates (2   107 cells/ 
sample) were immunoprecipitated by anti-Flag mAb, followed by Western 
blotting using anti-CARMA1 Ab. (C) Detection of I B  degradation was 
performed as in Fig. 1. (D) For detection of potentiality of these mutant TAK1 
kinase activity, each construct shown in A was transiently transfected with 
TAB1 into 293T cells. Cells were lysed and immunoprecipitated by anti-Flag 
mAb. The immunocomplexes were subjected to kinase assay using GST-IKK  
as a substrate. In lane 1 (asterisk), GST-IKK  in which S177 and S181 were 
mutated to A177 and A181 was used as a negative control substrate.
Figure 6. Interaction of TAK1 with CARMA1 is dependent on 
PKC . (A) For phosphorylation of CARMA1 in wild-type or PKC  /  DT40 
cells, immunoprecipitation and Western blotting were performed as Fig. 3 
B. (B) For association of TAK1 and CARMA1, cell lysates from TAK1- or 
PKC -deficient DT40 cells, both of which expressed Flag-tagged wild-type 
TAK1, were immunoprecipitated with anti-Flag mAb and analyzed by 
Western blotting using anti-CARMA1 Ab. (C) For interaction of CARMA1 
with Bcl10 or MALT1 in PKC  /  cells, cytosolic extracts from 4   107 
cells per sample were immunoprecipitated with anti-CARMA1 Ab and 
analyzed by Western blotting using anti-Bcl10 or -MALT1 Abs.PKC , TAK1, AND CARMA1 IN BCR SIGNALING | Shinohara et al. 1428
stimulation. As a further negative control, we also used a re-
combinant GST-IKK  mutant in which two conserved
serine residues (S177 and S181) in the activation loop of
IKK  were changed to alanine residues (Fig. 7 B, lane 4),
demonstrating that these sites are indeed phosphorylated by
immunoprecipitated TAK1. The aforementioned data raised
the possibility that either TAK1, or a kinase that may associate
with the TAK1 immunocomplex, is one of the IKK kinases.
DISCUSSION
Despite the importance of PKC  in BCR-induced IKK ac-
tivation, the underlying mechanism has remained unclear. In
this study, we provide several lines of evidence in support of
the critical role of PKC -mediated phosphorylation of
CARMA1 in bringing two key enzymes TAK1 and IKK
into close proximity with each other, thereby activating IKK
by BCR stimulation. A model for the mechanism of PKC -
mediated activation of IKK during BCR signaling, based on
the data presented here, is shown in Fig. 8. Involvement of
PKC  in BCR-mediated CARMA1 phosphorylation is
clear; however, our data has not addressed the issue of
whether PKC  phosphorylates CARMA1 after BCR stimu-
lation, directly or indirectly. In this regard, as in T cells,
PDK1 might facilitate the functional interaction between
PKC  and CARMA1 in B cells (42).
The initial phosphorylation of CARMA1 (3 min after
stimulation) mediated by PKC  is most likely to cause its as-
sociation with TAK1 and Bcl10/MALT1 complex, which is
supported by two lines of our observations. First, the com-
parison between wild-type and PKC -deficient DT40 cells
clearly showed the well correlation between the inducible
phosphorylation status of CARMA1 and its association with
TAK1, Bcl10, and MALT1 at 3 min after BCR stimulation
(Fig. 6). Second, BCR-mediated phosphorylation of
CARMA1 still occurred in TAK1-deficient DT40 cells (Fig.
3 B), implying that the initial CARMA1 phosphorylation
precedes its association with TAK1 during BCR signaling.
Next, the question of how CARMA1 phosphorylation
contributes to its association with Bcl10 and TAK1 arises.
CARMA1 contains a set of motifs (PDZ, SH3, and GUK
domains) that define MAGUK family proteins (29, 43). The
best characterized member of this family, PSD-95, forms rel-
atively stable, detergent-resistant, and microfilament-inde-
pendent multiprotein aggregations at postsynaptic membrane
densities in neurons (44, 45). Furthermore, it has been pro-
posed that the intramolecular interactions of PSD-95, such as
between the SH3 and GUK domains, keep it in a closed, in-
active conformation, whereas binding to a regulatory ligand
could induce an opening of the conformation that would al-
low for subsequent intermolecular SH3–GUK interactions
and dimerization or multimerization. In addition to
MAGUK-typical features, CARMA1 contains two addi-
tional protein–protein interaction domains; a CARD do-
main and a coiled-coil domain. The CARD domain of
CARMA1 is shown to mediate binding to Bcl10, whereas
its coiled-coil domain is thought to mediate homo- and/or
hetero-multimerization (23, 28, 32). Thus, it is reasonable to
anticipate that the initial phosphorylation of CARMA1 (3
min after stimulation), like the regulatory ligand, could in-
Figure 7. TAK1 is able to phosphorylate IKK. (A) For IKK recruitment 
to CARMA1, 2   107 cell lysates were immunoprecipitated by anti-IKK  
mAb and analyzed by Western blotting using anti-CARMA1 Ab. (B) Cell lysates 
from the transfectants, as seen in Fig. 2 D, were immunoprecipitated by 
anti-Flag mAb and performed in vitro kinase assay using GST-IKK  as a 
substrate. In the lane 4 (asterisk), GST-IKK  in which S177 and S181 were 
mutated to A177 and A181 was used as a negative control substrate.
Figure 8. A model for BCR-mediated NF- B activation. Stimulation 
of BCR leads to activation of proximal protein tyrosine kinases including 
Syk and Btk. Btk phosphorylates several tyrosine residues on phospholipase 
C- 2 (PLC- 2), and subsequent activation of protein kinase C  (PKC ). 
Activated PKC  phosphorylates CARMA1 (1), directly or indirectly, which 
is able to recruit TAK1 to the phosphorylated CARMA1 (2). Meanwhile, the 
IKK complex probably through the Bcl10/ MALT1 complex is recruited to 
the phosphorylated CARMA1 (3 and 4). These interactions (CARMA1-IKK 
and CARMA1-TAK1) contribute to access of two key protein kinases, TAK1 
and IKK, leading to activation of the IKK complex (5).JEM VOL. 202, November 21, 2005 1429
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duce the opening state from its closed conformation, thereby
allowing CARMA1 to form homo-oligomerization and het-
ero-oligomerization with signaling molecules, including
Bcl10 and TAK1. However, disparity between phosphoryla-
tion status of CARMA1 and its association with Bcl10 and
TAK1 (10 min after stimulation) was also observed. These
data suggest that CARMA1 might undergo phosphorylation
on several serine/threonine residues with distinct time kinet-
ics during BCR signaling and that the sites being phosphory-
lated with later time kinetics could contribute to terminating
these associations.
Although endogenous Bcl10 and MALT1 can be coim-
munoprecipitated from lysates of nonstimulated B and T
cells, the physical association of Bcl10 and MALT1 is not
clear (31). In the case of DT40 B cells, we observed that this
association was inducible (unpublished data). Given that
Bcl10 undergoes phosphorylation in antigen receptor signal-
ing (46, 47), this phosphorylation might contribute to further
association of Bcl10 and MALT1, thereby making a stable
CARMA1–Bcl10–MALT1 complex upon BCR engage-
ment. IKK  was recruited to CARMA1 after receptor liga-
tion (Fig. 7 A). Thus, the IKK complex including IKK 
might be directly associated with CARMA1–Bcl10–MALT.
It is also possible that TRAF6 and/or ECSIT (evolutionarily
conserved signaling intermediate in toll pathways) might
function as a connecting molecule between CARMA1–
Bcl10–MALT1 and the IKK complex (33, 34, 48).
Importance of phosphorylation of the activation loop
serine residues of IKK  and IKK  has been demonstrated in
vivo as well as in vitro experiments (37, 49, 50). As these
serine residues are not part of a PKC consensus phosphoryla-
tion site, two mechanistic ideas have been proposed. First,
other serine/threonine residues of IKK  and IKK  may
serve as direct substrates of PKC , thereby contributing to
IKK activation. Alternatively, PKC  may regulate IKK indi-
rectly through an intermediate kinase that would be directly
or indirectly controlled by PKC . Although the first possi-
bility cannot be completely excluded, our data highly sug-
gest that the second mechanism mainly operates in the BCR
signaling context and that TAK1 corresponds to this inter-
mediate kinase. First, consistent with a previous report using
Jurkat T cells (34), TAK1 was demonstrated to play a critical
role in BCR-mediated IKK activation in DT40 B cells. Sec-
ond, because PKC  activation occurred normally in the ab-
sence of TAK1, TAK1 is likely activated downstream of
PKC . Third, immunoprecipitated TAK1, but not its kinase
mutant, was able to phosphorylate activation loop serine
residues of IKK  in in vitro conditions.
In contrast with wild-type DT40 cells, TAK1 activation
status, as judged by antiphosho-serine/threonine Ab, was
greatly decreased in both PKC - and CARMA1-deficient
cells, suggesting involvement of PKC -mediated CARMA1
phosphorylation and probably subsequent association of
CARMA1 and TAK1 in its activation. In this regard, the dA
TAK1 mutant is thought to be devoid of a binding site to
TAB2, an adaptor molecule linking TRAF6 and TAK1 in
IL-1 receptor signaling (41). Thus, TAB2 could be one of
the candidates that contribute to association of CARMA1
with TAK1. In addition to TAK1 activation, substrate acces-
sibility is important. Association of both TAK1 and IKK
complex with CARMA1 and dependency of these associa-
tions on PKC  were clearly demonstrated by this study.
Hence, these associations likely allow the activated TAK1 to
phosphorylate IKK  in in vivo contexts. Furthermore, be-
cause MALT1 is reported to activate IKK by promoting the
ubiquitination of the IKK  directly, or indirectly through
TRAF6 (33–35), this IKK  ubiquitination may contribute
to bringing IKK  into a state that is more susceptible to being
phosphorylated by TAK1.
TAK1 was reported as a kinase coupling innate recep-
tors, Toll-like receptors/IL-1 receptors, to IKK activation
(12–17). Therefore, involvement of this kinase also in anti-
gen receptor–mediated IKK activation is somewhat surpris-
ing. Here, the relative lack of redundancy in BCR-mediated
IKK activation in DT40 cells has enabled us to provide an
insight into how TAK1 participates in adaptive immune re-
ceptor signaling such as through BCR. Phosphorylation of a
specific scaffold molecule, CARMA1, recruits actions of two
common NF- B players, TAK1 and IKK, into the adaptive
immune receptor signaling. Thus, the adaptive immune sys-
tem in vertebrates may have evolved from the more primi-
tive innate immune system through usurping the common
key signaling components of the NF- B pathway, including
TAK1 and IKK, by using CRAMA1–Bcl10–MALT1.
MATERIALS AND METHODS
Cells, mice, Abs, and reagents. Wild-type and various mutant DT40
cells were cultured in RPMI 1640 (GIBCO BRL and Invitrogen) supple-
mented with 10% FCS, 1% chicken serum, 50  M 2-ME (Sigma-Aldrich), 4
mM L-glutamine, and antibiotics. Wild-type C57BL/6J mice were purchased
from Clea Japan. Anti-CARMA1 Ab and anti-I B  Ab were obtained by im-
munizing rabbits with synthetic peptide (CLQFVSRSENKYKRMN-
SNERVRI) and with bacterially expressed GST fusion proteins containing
amino acid sequences coding chicken I B  (amino acids 1–103), respectively.
Anti–chicken IgM mAb, M4 (51), was used for stimulation of BCR and
FACS analysis. Anti-ERK Ab, anti-JNK Ab, anti-TAK1 mAb (C9), anti-
Bcl10 mAb (331.3), and anti-MALT1 Ab were purchased from Santa Cruz
Biotechnology, Inc. Anti–phospho-PKC  (T 500) Ab, anti-PKC II Ab, anti-
CARMA1 Ab, and anti-TAK1 Ab were obtained from Abcam. Anti-IKK 
mAb was obtained from BD Biosciences. Anti–phospho-ERK Ab, anti–phos-
pho-I B  mAb (5A5), anti–phospho-IKK /  (S177 /S181), and anti–phos-
pho-threonine Ab were purchased from Cell Signaling Technology Inc. Anti–
phospho-serine Ab was obtained from Zymed Laboratories. The mixture of
anti–phospho-serine and -threonine Ab were used as anti–phospho-serine/
threonine Ab. Anti-FLAG mAb (M2) was obtained from Sigma-Aldrich.
Expression constructs and transfection. Flag-tagged mouse wild-type
TAK1 and its mutant cDNAs were generated by PCR. Each cDNA was
cloned into the pApuro with IRES-GFP expression vector (52). Kinase-
dead TAK1, dA TAK1, and dB TAK1 harboured K63W point mutation,
internal deletion (amino acids 401–530), and COOH-terminal deletion
(amino acids 531–579), respectively. These constructs were transfected into
each mutant DT40 cells by electroporation as described elsewhere (51).
Generation of various deficient DT40 cells. Based on published se-
quence of murine PKC II, CARMA1, and TAK1, we searched eachPKC , TAK1, AND CARMA1 IN BCR SIGNALING | Shinohara et al. 1430
chicken homologue using the expressed sequence tag database and obtained
each chicken cDNA by RT-PCR with RNA from DT40 B cells. Genomic
clones of PKC II, CARMA1, and TAK1 were obtained by PCR using oli-
gonucleotides (designed from each cDNA sequence) and genomic DNA as
a template. The targeting vector, pPKC II-neo or pPKC II-hisD, was
constructed by replacing the genomic fragment containing exons that cor-
respond to murine PKC II ATP-binding domain with neo or hisD cas-
sette. The targeting constructs for CARMA1 were designed for neo and
hisD cassettes to replace the genomic fragment of chicken CARMA1 exons
2–7. The targeting constructs for TAK1 were designed for neo and hisD
cassettes to replace the genomic fragment corresponding to murine TAK1
ATP-binding domain. These targeting vectors were sequentially transfected
into DT40 cells, resulting in generation of PKC II-, CARMA1-, or
TAK1-deficient DT40 cells, as described previously (51).
Immunoprecipitation and Western blot analysis. For immunoprecip-
itation, cells were solubilized in NP-40 lysis buffer supplemented with pro-
tease and phosphatase inhibitors as described previously (51) and precleared
lysates were incubated with proper Abs and protein G–sepharose (GE Health-
care). For Western blot analysis, immunoprecipitates or cleared-cell lysates
were resolved on SDS-PAGE, transferred to polyvinyldifluoride (PVDF)
membrane (Bio-Rad Laboratories), and incubation with secondary horserad-
ish peroxidase–labeled (GE Healthcare) or alkaline phosphatase–labeled (Santa
Cruz Biotechnology, Inc.) Abs. The blots were washed and visualized with
the SuperSignal West Dura Extended Duration Substrate (Pierce Chemical
Co.) or BCIP/NBT Color Development system (Promega).
Electrophoretic mobility shift assay (EMSA). DNA-binding activity
of NF- B was analyzed by EMSA as described previously (52). In brief, the
nuclear extracts of DT40 cells (2   106) treated with 10  g/ml M4 were
purified, incubated with a specific probe for the NF- B DNA binding site
(5 -CAACGGCAGGGGAATTCCCCTCTCCTT-3 ), electrophoresed,
and visualized by autoradiography.
In vitro kinase assay. For IKK and TAK1 kinase assays, 2   107 DT40
cells stimulated with 10  g/ml M4 were lysed in 1% NP-40 lysis buffer. Pre-
cleared lysates were immunoprecipitated by 1  g anti-IKK  mAb or 1  g
anti-Flag mAb, followed by incubating with 40  l of protein G-sepharose.
The beads were washed three times with lysis buffer and two times with ki-
nase buffer (25 mM Tris, pH 7.5, 5 mM  -glycerolphosphate, 2 mM DTT,
0.1 mM Na3VO4, 10 mM MgCl2). Immunoprecipitates were resuspended in
kinase buffer containing 100  M ATP. GST-I B  (NH2-terminal of mouse
I B ; amino acids 1–72) or GST-IKK  (activation loop of human IKK ;
DLGYAKELDQGSLCTSFVGTLQYLAPELLEQQ or its mutant; DLGY-
AKELDQGALCTAFVGTLQYLAPELLEQQ) fusion protein (0.2  g each)
was added as a substrate for IKK or TAK1, respectively. After 30 min incuba-
tion at 30 C, the reaction was terminated by addition of SDS sample buffer
followed by boiling for 5 min. The samples were separated by SDS-PAGE
gel, transferred to PVDF membrane, and detected by anti–phospho-I B 
mAb or anti–phospho-IKK /  respectively. For JNK kinase assay, JNK ki-
nase assay kit (Cell Signaling Technology Inc.) was used according to the
manufacturer’s instructions.
Flow cytometric analysis. Cell surface expression of BCR on various
mutant DT40 cells was analyzed by FACSCalibur (Becton Dickinson) using
anti–chicken IgM Ab (Bethyl) conjugated with allophycocyanin (Dojindo).
Online supplemental material. Fig. S1 A shows protein expression in
DT40 wild-type, TAK1-, PKC -, and CARMA1-deficient DT40 B cells
analyzed by Western blot. Fig. S1 (B and C) depicts cell surface expression
of BCR on various mutant DT40 cells. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20051591/DC1.
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